First clinical trial with IPH2102/BMS-986015 sponsored by Bristol-Myers Squibb announced

• A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that a Phase I trial sponsored by Bristol-Myers Squibb was published on the NIH website ClinicalTrials.gov for IPH2102/BMS-986015 and is currently recruiting.

Marcel Rozencweig, Chief Medical Officer of Innate Pharma, said: “IPH2102/BMS-986015 will be tested in a variety of solid tumors, in combination with anti-PD-1 which has shown promising single agent results in Phase I/II trials.”